Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name TTI-621
Trade Name
Synonyms SIRPalpha-Fc|TTI621|TTI 621|Ontorpacept
Drug Descriptions

TTI-621 (Ontorpacept) is a fusion, consisting of SIRPa fused to the human IgG1 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells (PMID: 27856600, PMID: 28286286) may also stimulate cytotoxic T-cells (PMID: 29873856).

DrugClasses CD47 Antibody 26 Immune Checkpoint Inhibitor 151
CAS Registry Number 2131089-46-6
NCIT ID C125718


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Daratumumab + TTI-621 Daratumumab TTI-621 0 1
Doxorubicin + TTI-621 Doxorubicin TTI-621 0 1
Pembrolizumab + TTI-621 Pembrolizumab TTI-621 0 1
TTI-621 TTI-621 0 2

Additional content available in CKB BOOST